← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Color Health, Inc.
Burlingame, CA
$81,790,674
Total funding
2
Grants
Funding over time
peak $20.7M · FY2019–25$25M$18.8M$12.5M$6.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$81,790,674 · 2
By mechanism
OT2$81,790,674 · 2
Investigators at Color Health, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Color's software and services platform for the Return of Personalized Value to the All of Us Research Program participants$20,735,000
OT2 · FY2024 · OD
Color's software-powered, high-touch delivery of genetic counseling sessions and pharmacogenomics consultations for return of genomic results$15,144,656
OT2 · FY2022 · OD
Color's software-powered, high-touch delivery of genetic counseling sessions and pharmacogenomics consultations for return of genomic results$14,596,381
OT2 · FY2021 · OD
Color's software-powered, high-touch delivery of genetic counseling sessions and pharmacogenomics consultations for return of genomic results$11,217,770
OT2 · FY2020 · OD
Color's software-powered, high-touch delivery of genetic counseling sessions and pharmacogenomics consultations for return of genomic results$9,968,567
OT2 · FY2023 · OD
Color's software-powered, high-touch delivery of genetic counseling sessions and pharmacogenomics consultations for return of genomic results$5,233,866
OT2 · FY2019 · OD
Color's software-powered, high-touch delivery of genetic counseling sessions and pharmacogenomics consultations for return of genomic results$4,447,745
OT2 · FY2020 · OD
Color's software and services platform for the Return of Personalized Value to the All of Us Research Program participants$446,689
OT2 · FY2025 · OD